ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INDV Indivior Plc

1,565.00
-67.00 (-4.11%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Indivior Investors - INDV

Indivior Investors - INDV

Share Name Share Symbol Market Stock Type
Indivior Plc INDV London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-67.00 -4.11% 1,565.00 16:35:10
Open Price Low Price High Price Close Price Previous Close
1,664.00 1,537.00 1,664.00 1,565.00 1,632.00
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Top Investor Posts

Top Posts
Posted at 22/2/2024 15:10 by casholaa
In fairness to them, they've hived off money for the litigation so it doesn't distort net cash, they recognize that it's mainly a US market-driven company with mainly US investors, they are expanding globally, they are not a one-trick pony, they have been succeeding on the revenue front and return value to shareholders through buybacks for the time being.

*they also pointed out that they only recently started sales through pharmacy/private doctor dispensers

*global company in the making, we just happen to be poorer than our US counterparts
Posted at 05/12/2023 16:08 by waldron
Indivior PLC INDV Prevails in Striking Claims in UK Litigation (7595V)
05/12/2023 2:06pm
UK Regulatory (RNS & others)



Tuesday 5 December 2023


TIDMINDV

RNS Number : 7595V


Indivior Prevails in Striking Representative Claims from UK Shareholder Action

Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, announced that the High Court of Justice of England and Wales has issued a judgment striking out representative claims by Wirral Council as administering authority of Merseyside Pension fund ("Wirral") against Indivior under the Financial Services and Markets Act 2000 ("FSMA"). Wirral's suit was the first attempt by claimants to use representative proceedings for securities claims brought under Sections 90, 90A, and Schedule 10 of the FSMA. The proposed representative proceedings, if allowed, would permit a representative acting on behalf of unnamed claimants to attempt to prove a violation of law without proof of damages, in contrast to ordinary multi-party proceedings, which require proof of liability and damages for each claimant.

In September 2022, Wirral had filed a representative claim generally asserting that Indivior violated the FSMA by making misleading or dishonest statements regarding an alleged fraudulent scheme to switch the market for its SUBOXONE (R) branded products in published information relating to securities. A similar claim was filed against Reckitt Benckiser.

After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings. The Court specifically found that it "would be unfair and unjust, and contrary to the overriding objective, to allow the Representative Proceedings to oust the jurisdiction of the Court to case manage the claims from the start." The Court's judgment may be found here .

Wirral and other claimants separately had filed a multi-party action generally alleging the same claims, and levied similar allegations against Reckitt Benckiser Group PLC ("Reckitt Benckiser") in separate actions. Pursuant to the Court's judgment, the claim against Indivior may only proceed in those multi-party proceedings brought by the claimants named in those proceedings.

Wirral may seek permission to appeal the Court's judgment.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.

Media Contacts :

US Media :

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

UK Media :

Teneo

Tel: +44 207-353-4200

Investors and Analysts :

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

-ends-





(END) Dow Jones Newswires

December 05, 2023 09:06 ET (14:06 GMT)
Posted at 09/11/2023 07:38 by ariane
SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.

Indivior (PRNewsfoto/Indivior)

The earnings release can be found at www.indivior.com/investors

The investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)

There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below.

Webcast link:
Participants may access the presentation telephonically by registering with the following link: [...]
Posted at 27/7/2023 09:01 by gregmorg
I am afraid the market reaction is the never ending litigation issues and the way the company has spelt it out in the notes this time. Nothing has changed according to the company but investors are bound to run from comments such as these.I am dissappointed to see this given I remain a LT holder
Posted at 30/5/2023 09:29 by steeplejack
Perhaps on our demise (hopefully not before)some of the more active private investors will be stuffed and exhibited in a museum.I will keep a wary eye out for roaming taxidermists.
Posted at 27/5/2023 12:34 by dealy
I would say the death of the retail stock picker / investor is pretty much universal. Hardly anyone i know across many countries would even consider buying a single share (other than the uber caps like Apple).For most small and mid caps the only way to get a reasonable valuation is to sell the company, but that is an activity which is also in the doldrums. Dividends and buy backs can help but that requires profits and no nasties on the horizon
Posted at 24/5/2023 06:47 by steeplejack
Executives see the US as an environment that embraces higher growth, while they bemoan the lack of interest from UK-based investors in their home market, particularly pension funds that have increasingly shunned British stocks over the past two decades.

“There are no domestic equity investors here — everything else is a symptom,” said Michael Tory, founder of advisory firm Ondra Partners. “It’s not about the listing rules, the governance or the free float requirements. Global investors look to domestic investors for the signal to validate the investment, and that local signal has simply flickered out.”
Posted at 27/4/2023 14:11 by casholaa
No need to pump as it's likely beyond the reach of many retails investors, but this sounds good to me:

"Indivior now anticipates net revenue of between USD970 million and USD1.04 billion, a 12% increase from the mid-point of 2022. In February the company had said it expected net revenue of between USD950 million and USD1.02 billion this year."
Posted at 29/3/2023 13:58 by steeplejack
Thereagain,GW Phamaceuticals abandoned AIM a few years back and listed on Nasdaq and was then taken over by Jazz Pharmaceuticals in 2021.Since MIFID2,research coverage for small,mediumUK companies (on the AIM market in particular) has diminished.Indivior is a FT250 constituent but it could well attract better research coverage in the USA and there are currency considerations.US funds might well be reticent to purchase sterling denominated stocks or pay UK government stamp duty for that matter.In any event,Indivior’;s main market is the US and anything which makes the stock more accessible to US investors is eminently sensible.Nowadays,global markets would suggest that things on different exchanges get pretty much equalised but there are clear investor relations advantages in being a quoted vehicle in your primary market.As for the good old UK LSE,the daily traded turnover in heavyweights like Amazon and Apple regularly exceeds the total daily turnover on the UK market.
Posted at 07/12/2022 07:52 by grupo guitarlumber
07 December 2022

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation

and Attractive Medium-Term Profitable Growth Outlook

- Peak Annual Net Revenue Potential for SUBLOCADE (R) Increased to >$1.5 Billion

- Attractive and Scalable Business Outlined - Expects Strong Net Revenue Growth and Operating Margin Expansion Over the Medium-term

- Disciplined Approach to Capital Allocation Maintained

- NASDAQ Listing Targeted for Spring 2023

This Release Contains Inside Information.

Slough, UK, and Richmond, VA, December 7, 2022 - Indivior PLC (LON: INDV) will hold a Capital Markets Day today in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.

"We have made tremendous progress executing on our strategic priorities," said Mark Crossley. "We are the pioneer and global leader in addiction treatment and science and are well-positioned to transform the lives of the increasing number of patients affected by the opioid crisis, one of the most urgent public health emergencies of our time. Today, my team and I are excited to provide a deep review of our business and to highlight the compelling opportunities we have to innovate in the treatment of addiction and serious mental illness while delivering profitable growth and significant value creation for shareholders."

-- Increases SUBLOCADE peak annual net revenue (NR) expectations to >$1.5 billion

Indivior expects SUBLOCADE(R) (buprenorphine extended-release) injection to achieve a NR run rate of $1 billion by the end of 2025, driven by its focus on further developing the Organized Health Systems (OHS) channel and pursuing the large opportunity in the U.S. Justice System. Longer term, based on the expected positive market dynamics for buprenorphine medication-assisted treatment (BMAT) and on continued execution against its OHS strategy, Indivior now expects to deliver SUBLOCADE peak potential NR of >$1.5 billion.

-- Expects to achieve attractive double-digit % NR compounded annual growth rate (CAGR) over the medium-term

Indivior expects to achieve a double-digit percentage NR CAGR over the medium-term, driven primarily by SUBLOCADE in the United States and growing NR contribution from PERSERIS(R) (risperidone for extended-release injection). Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEX (R) PR) and SUBOXONE (R) (buprenorphine/naloxone) Film. Additionally, the Company assumes the U.S. market share of SUBOXONE Film, which it does not promote, will trend towards historical analogs for genericized medicines.

-- Operating margin expansion opportunity from scalable business model

Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses. Following the significant structural growth investments behind SUBLOCADE and PERSERIS in the past two years, selling, general and administrative (SG&A) expenses are expected to grow at a more moderate pace and to decline as a percentage of NR. This impact is expected to be partly offset by an increase in R&D expenses as a percentage of NR towards industry benchmarks as the Company seeks to build a strong and balanced pipeline focused on addiction treatments.

-- Disciplined capital allocation approach focused on driving growth and potential returns of excess cash

In the past two years, Indivior's healthy balance sheet and improved cash flow have supported a balanced approach towards capital allocation, focused on investment in key growth priorities, diversifying the business, delivering shareholder returns and meeting other stakeholder obligations. The recently announced definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) is indicative of Indivior's commitment to diversify its product portfolio and to expand its global leadership in addiction treatment and science.

-- Listing on NASDAQ targeted for the Spring of 2023

At its Extraordinary General Meeting (EGM) in September of this year, Indivior received strong support from its shareholders for an additional share listing in the United States. Having carefully evaluated the available options, Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing is expected to elevate Indivior's profile in the Company's largest market and to attract a broader group of biopharma-focused investors and analysts.

The Group reiterates its FY 2022 guidance published on October 27, 2022.

Event Details

Today's event will begin at 8:30am EST and conclude at 12:30pm EST. Due to limited availability, in-person participation is limited to institutional investors and analysts. For those wishing to attend in person, please RSVP to investorrelations@indivior.com and further location details will be provided.

Further details can be found at cmd.indivior.com

To access the live webcast, please click INDV CMD 2022 .

A webcast replay will be available after the event has concluded.

The person responsible for making this announcement is Kathryn Hudson, Company Secretary.

Your Recent History

Delayed Upgrade Clock